ASX - Delayed Quote AUD

Biotron Limited (BIT.AX)

Compare
0.0170 -0.0010 (-5.56%)
At close: December 13 at 4:10:55 PM GMT+11

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director 385.35k -- --
Mr. Peter James Nightingale B.Econ, CA Company Secretary 120k -- 1957
Dr. Stephen L. Becker M.D. Chief Medical Officer -- -- --

Biotron Limited

56 Delhi Road
Suite 3.3 North Ryde
Sydney, NSW 2113
Australia
61 2 9805 0488 https://www.biotron.com.au
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.

Corporate Governance

Biotron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 25, 2025 at 10:59 AM UTC - March 3, 2025 at 12:00 PM UTC

Biotron Limited Earnings Date

Recent Events

Related Tickers